Gasser Elizabeth Anne 4

What Happened
Elizabeth A. Gasser, EVP & Chief Strategy Officer of Tandem Diabetes Care (TNDM), reported multiple May 15, 2026 transactions: she converted/ exercised a total of 10,267 derivative shares (likely RSU/award conversions) and had 5,510 shares withheld to satisfy tax withholding (no open‑market sale). Separately, she purchased 1,337 shares under the company’s ESPP at $10.90/share for $14,573. The withheld shares covered $70,638 of tax liability at $12.82/share. Net new shares to her (converted + ESPP − withheld) = 6,094.

Key Details

• Transaction date: May 15, 2026; Form 4 filed May 19, 2026 (timely).
• Derivative conversions/exercises: 1,503 + 1,097 + 7,667 = 10,267 shares acquired at $0 (conversion).
• Tax withholding: 807 + 589 + 4,114 = 5,510 shares withheld at $12.82 each; total value withheld = $70,638. (Footnote F1: shares withheld by company to satisfy tax withholding; no shares sold.)
• ESPP purchase / other acquisition: 1,337 shares @ $10.90 = $14,573 (footnote F2: ESPP purchase period Nov 18, 2025–May 15, 2026).
• Awards and vest schedules referenced in footnotes: several RSU awards (awarded in 2023–2025) with 33% vesting on applicable May 15 dates and remainder vesting in quarterly installments (see F4–F10).
• Some shares are held in The Gasser Family Trust (footnote F3).
• The filing does not state total shares beneficially owned after these transactions in the excerpt provided.

Context

• The large zero‑price “exercise/conversion” lines reflect conversion/settlement of derivative awards (RSUs/awards) into common stock rather than an open‑market purchase; the withheld shares (F code) were used solely for tax withholding.
• ESPP purchases (reported voluntarily) are straightforward employee purchases and are generally considered a modest bullish signal compared with open‑market insider buys.
• No late filing was indicated; the Form 4 was filed within the SEC’s required timeframe.